ReviewCurrent neuropharmacology2018
Neuroprotective Role of Agmatine in Neurological Diseases.
Review in Current neuropharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 95 citations in OpenAlex.
- Efficacy of l-Arginine treatment in patients with HTLV-1-associated neurological disease.Annals of clinical and translational neurology · 2023Trial
- Trial
- Age-Specific Ex Vivo Modulation of Gut-Brain Axis-Associated Metabolites by Galacto-Oligosaccharides and Nutrient Blends in Early Childhood.Metabolites · 2026Article
- Increased Agmatine Degradation in Children with Specific Learning Disorder.International journal of molecular sciences · 2026Article
- The effects of agmatine treatment on cisplatin-induced hepatotoxicity: an experimental rat study.Sao Paulo medical journal = Revista paulista de medicina · 2026Article
- Neuroinflammation leads to pharmacoresistance in temporal lobe epilepsy via promoting spermine degradation.Acta pharmacologica Sinica · 2025Article
- Impact of agmatine on cerebral astrocyte reactivity, neurodegeneration, and oxidative stress in bile duct-ligated rats.Metabolic brain disease · 2025Article
- Agmatine Mitigates Diabetes-Related Memory Loss in Female Mice by Targeting IAntioxidants (Basel, Switzerland) · 2025Article
- The Role of Agmatine in Modulating Autophagy Under Neuroinflammatory Conditions Induced by Metabolic Alteration in Mouse Brain.Experimental neurobiology · 2025Article
- The Neuroprotective Effects of Agmatine on Parkinson's Disease: Focus on Oxidative Stress, Inflammation and Molecular Mechanisms.Inflammation · 2025Review
- Article
- Agmatine Abrogates Tacrolimus-Induced Testicular Injury in Rats.Pharmaceutics · 2025Article
- Nitrogen waste metabolism as a locus of nitrergic co-transmission in the brain.Frontiers in behavioral neuroscience · 2025Review
- Yeast protein modulates metabolites derived from the human gut microbiota of older male adultsFrontiers in microbiology · 2025Article
- Altered gut microbial networks and metabolic pathways in multiple system atrophy: a comparative 16S rRNA study.Frontiers in neuroscience · 2025Article
- Therapeutic Potential of Agmatine in Essential Tremor Through Regulation of Lingo-1 and Inflammatory Pathways.Brain and behavior · 2025Article
- Evidence for safety of the dietary ingredient agmatine sulfate as assessed by mutagenicity and genotoxicity studies.Toxicology reports · 2024Article
- Exploring the clinical connections between epilepsy and diabetes mellitus: Promising therapeutic strategies utilizing agmatine and metformin.Naunyn-Schmiedeberg's archives of pharmacology · 2024Review
- Regulation of I1-imidazoline receptors on the sedation effect of dexmedetomidine in mice.Naunyn-Schmiedeberg's archives of pharmacology · 2024Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeurological diseases have always been one of the leading cause of mobility and mortality world-widely. However, it is still lacking efficient agents. Agmatine, an endogenous polyamine, exerts its diverse biological characteristics and therapeutic potential in varied aspects.
methodsThis review would focus on the neuroprotective actions of agmatine and its potential mechanisms in the setting of neurological diseases.
resultsNumerous studies had demonstrated the neuroprotective effect of agmatine in varied types of neurological diseases, including acute attack (stroke and trauma brain injury) and chronic neurodegenerative diseases (Parkinson's disease, Alzheimer's disease). The potential mechanism of agmatine induced neuroprotection includes anti-oxidation, anti-apoptosis, anti-inflammation, brain blood barrier (BBB) protection and brain edema prevention.
conclusionsThe safety and low incidence of adverse effects indicate the vast potential therapeutic value of agmatine in the treatment of neurological diseases. However, most of the available studies relate to the agmatine are conducted in experimental models, more clinical trials are needed before the agmatine could be extensively clinically used.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.